ABN AMRO Bank N.V. Buys 33,418 Shares of Boston Scientific Corporation $BSX

ABN AMRO Bank N.V. increased its stake in Boston Scientific Corporation (NYSE:BSX) by 68.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 82,199 shares of the medical equipment provider’s stock after buying an additional 33,418 shares during the quarter. ABN AMRO Bank N.V.’s holdings in Boston Scientific were worth $7,979,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BSX. HighPoint Advisor Group LLC boosted its holdings in Boston Scientific by 4.9% in the third quarter. HighPoint Advisor Group LLC now owns 53,443 shares of the medical equipment provider’s stock worth $5,218,000 after acquiring an additional 2,495 shares in the last quarter. SouthState Bank Corp increased its holdings in shares of Boston Scientific by 1.0% during the third quarter. SouthState Bank Corp now owns 168,997 shares of the medical equipment provider’s stock valued at $16,499,000 after acquiring an additional 1,670 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Boston Scientific by 13.9% in the 3rd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 205,680 shares of the medical equipment provider’s stock worth $20,081,000 after purchasing an additional 25,136 shares during the last quarter. Gallacher Capital Management LLC bought a new position in Boston Scientific in the 3rd quarter worth about $420,000. Finally, Savant Capital LLC grew its position in Boston Scientific by 3.9% during the 3rd quarter. Savant Capital LLC now owns 22,072 shares of the medical equipment provider’s stock valued at $2,155,000 after purchasing an additional 836 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
• Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
• Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Evercore ISI set a $112.00 target price on shares of Boston Scientific in a report on Monday, January 5th. Citigroup restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, January 14th. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Monday. Canaccord Genuity Group decreased their price target on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $121.84.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 17.6%

Boston Scientific stock opened at $75.50 on Thursday. Boston Scientific Corporation has a 52-week low of $75.00 and a 52-week high of $109.50. The company has a market cap of $111.92 billion, a P/E ratio of 40.37, a P/E/G ratio of 1.63 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The business has a 50-day simple moving average of $94.37 and a two-hundred day simple moving average of $99.13.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.